Drug or treatment

Cemiplimab clinical trials

• 55Clinical trials
• 1New in 30 days
• 22Countries

Newest trials

All recruiting trials (55)

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Combining gemcitabine, cisplatin, nab-paclitaxel and cemiplimab to shrink locally advanced biliary tract cancer

  This trial will try whether giving gemcitabine, cisplatin, nab-paclitaxel plus cemiplimab can shrink previously inoperable biliary tract cancers so surgery becomes possible.

  Recruiting Phase 2 Columbia University · New York, New York · NCT07433673

• Neoadjuvant Cemiplimab for Merkel Cell Carcinoma in Stage I–II

  This study tests whether giving Cemiplimab before surgery helps people with early-stage Merkel cell carcinoma see if tumors shrink or disappear before sentinel node biopsy.

  Recruiting at 11 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Heidelberg, Baden-Wurttemberg and 11 other locations · NCT07387198

• Capecitabine/Oxaliplatin chemo with cemiplimab with or without fianlimab or REGN7075 for locally advanced rectal cancer

  This trial tests whether adding cemiplimab, cemiplimab with fianlimab, or cemiplimab with REGN7075 to CAPOX can help people with MSS locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07281768

• Adding cemiplimab to chemotherapy before surgery for sinonasal squamous cell carcinoma

  This test checks whether adding the immunotherapy cemiplimab to carboplatin and paclitaxel before surgery helps people with locally advanced sinonasal squamous cell carcinoma.

  Recruiting at 18 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 17 other locations · NCT07281417

• Cemiplimab plus TEDOPI maintenance for ctDNA‑positive HLA‑A2 advanced NSCLC

  This trial will test whether adding the TEDOPI vaccine to cemiplimab as maintenance can clear circulating tumor DNA in HLA‑A2 positive advanced NSCLC patients who did not progress after four cycles of chemo‑immunotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, RM · NCT07264673

• Cemiplimab with topical imiquimod and fractional laser before surgery for high‑risk basal cell carcinoma

  This tests whether giving cemiplimab together with topical imiquimod and fractional laser before surgery can boost the immune response and lower the chance high‑risk, resectable basal cell carcinoma comes back.

  Recruiting at 4 sites Phase 1/2 Instituto Oncológico Dr Rosell · Barcelona, Barcelona and 3 other locations · NCT07251413

• Cemiplimab alone or with fianlimab after stereotactic body radiation for oligometastatic clear cell kidney cancer

  This trial will test whether giving cemiplimab alone or with fianlimab after stereotactic body radiation helps people with oligometastatic clear cell kidney cancer stay free of recurrence longer.

  Recruiting Phase 2 University of Oklahoma · Oklahoma City, Oklahoma · NCT07223541

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• First-line immune-checkpoint antibody combinations for advanced clear cell kidney cancer

  This trial tests whether combining fianlimab and cemiplimab, with or without ipilimumab, works better than the standard ipilimumab plus nivolumab as first treatment for people with advanced clear cell kidney cancer.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Washington D.C., District of Columbia and 4 other locations · NCT07188896

• Two immunotherapies after treatment for HPV-positive head and neck cancer

  This study tests whether adding fianlimab to cemiplimab helps prevent recurrence in adults with HPV-positive head and neck cancer who have detectable residual disease after initial therapy.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT07179315

• Pidnarulex plus cemiplimab for refractory microsatellite-stable colorectal cancer.

  This tests whether combining pidnarulex with cemiplimab is safe and can help people whose microsatellite-stable colorectal cancer has stopped responding to standard treatments.

  Recruiting at 7 sites Phase 1/2 National Cancer Institute (NCI) · Aurora, Colorado and 6 other locations · NCT07147231

• Cemiplimab maintenance for advanced adrenocortical carcinoma

  This trial will test whether giving cemiplimab as maintenance immunotherapy after first-line EDP-M chemotherapy can delay progression in adults with advanced adrenocortical carcinoma who achieved a response or stable disease.

  Recruiting Phase 2 Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia, Brescia · NCT07085572

• Next‑generation immune profiling to find response and toxicity markers in skin cancer patients treated with cemiplimab

  This project will test whether advanced blood and tumor immune profiling can help predict who with advanced cutaneous squamous cell carcinoma will benefit from cemiplimab and who may develop side effects.

  Recruiting Instituto de Investigación Biomédica de Salamanca · Salamanca, Salamanca · NCT07064330

• Cemiplimab alone or with Fianlimab or REGN7075 after surgery and chemo in colorectal cancer with minimal residual disease

  This study tests whether cemiplimab alone or in combination with fianlimab or REGN7075 can help prevent colorectal cancer from returning in adults who are ctDNA-positive after standard treatment.

  Recruiting at 13 sites Phase 2 NSABP Foundation Inc · Gainesville, Florida and 12 other locations · NCT07058012

• Cemiplimab treatment for incurable metastatic or unresectable NUT carcinoma

  This trial will test whether the immunotherapy drug cemiplimab can help people whose NUT carcinoma has spread or cannot be removed by surgery.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT07050186

• Reduced-dose carboplatin doublet plus cemiplimab versus cemiplimab alone for older, frail metastatic NSCLC with PD-L1 under 50%

  This will test whether adding lower-dose carboplatin-based doublet chemotherapy to cemiplimab helps people aged 70 and older who are frail and have metastatic NSCLC with PD-L1 under 50% do better than cemiplimab alone.

  Recruiting at 18 sites Phase 2 Swiss Cancer Institute · Fribourg, Villars-sur-Glâne and 17 other locations · NCT07020065

• Oral pooled fecal microbiotherapy (MaaT033) with cemiplimab to try to reverse antibiotic-related resistance in advanced NSCLC

  This trial will try whether taking an oral pooled fecal microbiotherapy (MaaT033) together with cemiplimab can restore response to immunotherapy in adults with advanced non-small cell lung cancer who became resistant after taking antibiotics.

  Recruiting at 3 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 5 other locations · NCT07001618

• Cemiplimab as first-line treatment for advanced basal cell carcinoma

  This trial will try cemiplimab as a first-line treatment for adults with locally advanced basal cell carcinoma who have not received hedgehog inhibitors.

  Recruiting at 8 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Erfurt and 7 other locations · NCT06981325

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Adjuvant cemiplimab after complete surgery for stage II–IIIA non-small cell lung cancer in patients who have not had chemotherapy

  This trial tests whether giving cemiplimab after complete surgery can help prevent cancer from coming back in people with stage II–IIIA non-small cell lung cancer who did not receive chemotherapy.

  Recruiting at 26 sites Phase 3 ETOP IBCSG Partners Foundation · Vienna and 34 other locations · NCT06931717

• Using cemiplimab and fianlimab before surgery for non-small cell lung cancer

  This study is testing a combination of two drugs, cemiplimab and fianlimab, before surgery to see if they can help people with stage IB-IIIB non-small cell lung cancer respond better to treatment.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Jacksonville, Florida and 1 other locations · NCT06918132

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

• THIO plus cemiplimab versus chemotherapy for third-line advanced non-small cell lung cancer

  This trial tries giving THIO followed by the PD‑1 drug cemiplimab versus standard chemotherapy in adults with advanced or metastatic non-small cell lung cancer who have already had two prior treatments including an immune checkpoint inhibitor and platinum chemotherapy.

  Recruiting at 15 sites Phase 3 Maia Biotechnology · Poznan and 14 other locations · NCT06908304

• Combining XL092 and cemiplimab for BRAF V600E–wildtype anaplastic thyroid cancer

  This trial will test whether giving XL092 plus cemiplimab before surgery is safe and doable for adults with BRAF V600E–wildtype anaplastic thyroid cancer.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Boston, Massachusetts and 1 other locations · NCT06902376

• Adding cabozantinib to cemiplimab for adolescents and adults with advanced adrenocortical cancer

  This test sees if adding the targeted drug cabozantinib to the immunotherapy cemiplimab helps adolescents and adults with advanced, unresectable, recurrent, or metastatic adrenocortical cancer.

  Recruiting at 80 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 80 other locations · NCT06900595

• Treatment for BRAF Mutant Melanoma with Brain Metastases

  This study tests a new combination treatment for people with BRAF-mutated melanoma that has spread to the brain to see if it helps them live longer without their cancer getting worse.

  Recruiting at 17 sites Phase 2 Grupo Español Multidisciplinar de Melanoma · A Coruña, A Coruña and 17 other locations · NCT06887088

• Cemiplimab plus Y-90 radioembolization for breast cancer that has spread to the liver

  This trial tests whether giving the immunotherapy cemiplimab together with Y-90 liver radioembolization can boost immune attack and shrink tumors in people whose breast cancer has spread mainly to the liver.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06860815

• REGN5678 with cemiplimab for metastatic castration-resistant prostate cancer

  This trial tests whether combining REGN5678 (a PSMAxCD28 bispecific antibody) with cemiplimab (an anti‑PD‑1 drug) is safe and shows signs of activity in men with metastatic castration‑resistant prostate cancer who have progressed after prior therapies.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT06826768

• Cemiplimab plus gemcitabine for metastatic pancreatic cancer with SWI/SNF gene changes

  This trial will test whether adding the immunotherapy cemiplimab to the chemotherapy gemcitabine helps people with metastatic pancreatic ductal adenocarcinoma who have SWI/SNF genetic alterations and have already received one prior chemotherapy regimen.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT06790602

• Adding fianlimab to cemiplimab versus cemiplimab alone for recurrent or metastatic head and neck squamous cell carcinoma

  This test sees if adding the experimental drug fianlimab to cemiplimab works better than cemiplimab alone for people with recurrent or metastatic PD-L1–positive head and neck squamous cell carcinoma.

  Recruiting at 38 sites Phase 2 Regeneron Pharmaceuticals · Los Angeles, California and 37 other locations · NCT06769698

• Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC

  This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec and 1 other locations · NCT06743581

• Using cemiplimab and fianlimab before kidney cancer surgery

  This study is testing whether giving two immunotherapy drugs before kidney cancer surgery can safely shrink tumors in patients with high-risk non-metastatic clear cell renal cell carcinoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06699602

• SAR444881 plus cemiplimab for advanced solid tumors

  This trial tests SAR444881 together with cemiplimab in adults with advanced solid tumors (including non‑small cell lung, MSS colorectal, and ovarian cancer) to look for biomarkers tied to response and safety.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06651593

• Combining cemiplimab with standard treatment for advanced lung cancer

  This study is testing if adding the immunotherapy drug cemiplimab to standard treatments can help people with advanced lung cancer live longer and feel better compared to just the standard treatments alone.

  Recruiting at 399 sites Phase 2/3 SWOG Cancer Research Network · Daphne, Alabama and 412 other locations · NCT06616584

• Testing a new combination treatment for advanced melanoma

  This study is testing a new combination of three treatments for people with advanced melanoma that hasn't improved with other therapies to see if it can help them feel better.

  Recruiting at 12 sites Phase 2 Memorial Sloan Kettering Cancer Center · Los Angeles, California and 11 other locations · NCT06594991

• Using cemiplimab to treat early-stage skin cancer

  This study tests if injecting a new immune treatment called cemiplimab directly into early-stage skin cancer can work better than regular surgery.

  Recruiting at 50 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 52 other locations · NCT06585410

• All-trans retinoic acid (ATRA) plus cemiplimab for advanced leiomyosarcoma

  This trial will try combining oral all-trans retinoic acid with the immunotherapy cemiplimab to see if it can shrink tumors or slow progression in adults with metastatic or unresectable leiomyosarcoma after standard chemotherapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06528769

• Using cemiplimab and cetuximab before surgery for recurrent oral cavity cancer

  This study is testing if the drugs cemiplimab and cetuximab can help control recurrent oral cavity cancer before surgery to improve patient outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06448026

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called REGN10597 to see if it is safe and effective for adults with advanced solid tumors like melanoma and kidney cancer.

  Recruiting at 11 sites Phase 1/2 Regeneron Pharmaceuticals · Los Angeles, California and 10 other locations · NCT06413680

• Combination treatment for advanced colorectal cancer with specific mutations

  This study is testing a combination of three drugs to see if they can help people with advanced colorectal cancer that has specific mutations after they've already tried other treatments.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT06412198

• Neoadjuvant chemotherapy for non-small cell lung cancer

  This study is testing if adding a new drug called alirocumab to standard chemotherapy helps people with early-stage non-small cell lung cancer have better results after surgery.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06385262

• Combining two experimental drugs for advanced melanoma treatment

  This study is testing if a new combination of two experimental drugs can help people with advanced melanoma more than the current approved treatments.

  Recruiting at 92 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 112 other locations · NCT06246916

• Cemiplimab with or without Fianlimab for older patients with advanced colorectal cancer

  This study is testing whether a new combination of two immunotherapy drugs can help older patients with advanced colorectal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06205836

• Combining Cemiplimab and Ziv-Aflibercept for Metastatic Uveal Melanoma

  This study is testing if the combination of Cemiplimab and Ziv-Aflibercept can help shrink tumors or stop their growth in people with metastatic uveal melanoma who have already tried other treatments.

  Recruiting at 4 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Los Angeles, California and 3 other locations · NCT06121180

• Combination treatment for early-stage lung cancer

  This study is testing a combination of two medications, dupilumab and cemiplimab, to see if they can help people with early-stage lung cancer before surgery.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06088771

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Using Cemiplimab with or without chemotherapy for HPV-related head and neck cancer

  This study is testing if a new immunotherapy called Cemiplimab, with or without chemotherapy, can help people with HPV-related head and neck cancer while making treatment easier and improving their quality of life.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT04988074

• Using Cemiplimab before surgery for skin cancers

  This study is testing if giving a new immunotherapy drug before surgery can help people with certain types of skin cancer have better outcomes.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT04975152

• Combining chemotherapy and immunotherapy for head and neck cancer treatment

  This study is testing if combining chemotherapy with immunotherapy drugs can help people with head and neck cancer before surgery and possibly reduce the need for radiation therapy afterward.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04722523

• Investigating the safety and effectiveness of REGN5668 with other drugs for advanced ovarian and uterine cancers

  This study is testing if a new drug called REGN5668, used with other medications, can safely help people with advanced ovarian or uterine cancers.

  Recruiting at 27 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 27 other locations · NCT04590326

• Evaluating the safety and effectiveness of REGN5678 alone or with cemiplimab for advanced prostate and kidney cancer

  This study is testing if a new drug called REGN5678, alone or with another drug called cemiplimab, can safely shrink tumors in adults with advanced prostate and kidney cancer.

  Recruiting at 26 sites Phase 1/2 Regeneron Pharmaceuticals · Gilbert, Arizona and 26 other locations · NCT03972657

• Treatment for recurrent ovarian and other MUC16+ cancers using REGN4018 and cemiplimab

  This study is testing if a new treatment combining REGN4018 and cemiplimab can help adults with recurrent ovarian and other MUC16+ cancers feel better when other options have run out.

  Recruiting at 49 sites Phase 1/2 Regeneron Pharmaceuticals · Birmingham, Alabama and 53 other locations · NCT03564340

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

Quick answers

How many clinical trials of Cemiplimab are recruiting right now?

55, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in United States (42 trials), Spain (8 trials), France (5 trials), Italy (5 trials), Australia (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 31, Phase 1/2: 9, Phase 1: 6, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →